AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06426654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintiliman plus LDRT
Description: All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles.
Study NCT06342258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultradent Ultra Seal XT Plus
Description: Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
Study NCT05587140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture like TENS
Description: Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
Study NCT05587140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Description: Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
Study NCT05587140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TENS
Description: Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
Study NCT05415683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DV-SSP Imaging
Description: DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
Study NCT04974489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-based messages about the harm of VLNC
Description: Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
Study NCT04974489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued-harm-framed messages about the harm of VLNC
Description: Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
Study NCT04974489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myth-refuting messages about the harm of VLNC
Description: Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
Study NCT04974489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control messages about littering
Description: Participants in this arm will receive 3 control messages about littering during the survey data collection.
Study NCT04656470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
Study NCT05905289 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: no intervention as it is an observational study
Study NCT04855929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion
Study NCT04855929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered by intravenous (IV) infusion
Study NCT06337422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg capsule
Description: Celecoxib 200 mg capsule
Study NCT06337422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg capsule
Description: Celecoxib 200 mg capsule
Study NCT05909683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.
Description: After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
Study NCT05909683 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
Study NCT06418893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target control infusion propofol
Description: target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
Study NCT06418893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational isoflurane
Description: Inhalational Isoflurane at concentration 1-2%
Study NCT06456931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Buddhist mindfulness
Description: Details are provided in the arm/group descriptions.
Study NCT06456931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: secular mindfulness based cognitive therapy
Description: Details are provided in the arm/group descriptions.
Study NCT06570057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory, learning and Action (PLA) Based intervention
Description: An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
Study NCT04732169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active study drug ( oral CBD)
Description: CBD in single dose syringes
Study NCT04732169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
Study NCT06154538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: PD-1/CTLA-4 bi-specific antibody
Study NCT06154538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX chemotherapy
Study NCT06154538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: FOLFOX chemotherapy
Study NCT03634189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
Study NCT05536284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate Tablets
Description: Antihypertensive drug used for acute coronary syndrome patients
Study NCT06169241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot extract
Description: Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
Study NCT06169241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Study NCT04749693 — intervention group
Intervention type: DEVICE
Intervention: DBLG1 System
Description: Use of DBLG1 System in real life condition
Study NCT05129670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcite chewing gum
Description: The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
Study NCT05129670 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unmatched Placebo chewing gum
Description: The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
Study NCT06340061 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
Study NCT06039488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session.
Study NCT06244017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG spectrogram
Description: In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
Study NCT06244017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: In the control group, the general anesthesia is guided by using the bispectral index
Study NCT04480372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
Study NCT04480372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
Study NCT02919189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
Study NCT06270329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Description: Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase
Study NCT06270329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy program
Description: Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
Study NCT06119035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single dose of 75 grams glucose in 200ml water
Description: Consume single dose of 75 grams glucose in 200ml water
Study NCT05377411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
Study NCT05377411 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
Study NCT05377411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
Study NCT05686954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO LOW
Description: Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
Study NCT05686954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO MID
Description: Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
Study NCT05686954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO HIGH
Description: Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
Study NCT05686954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
Study NCT06033053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Description: The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
Study NCT06033053 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Description: The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
Study NCT05194865 — intervention group
Intervention type: DEVICE
Intervention: cardiac MRI
Description: assessment of the viability using CMR
Study NCT05194865 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: direct revascularization using PCI
Study NCT06511050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumbrokinase
Description: Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
Study NCT05755165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression
Description: \~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
Study NCT05755165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression, adjusted
Description: \~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
Study NCT05755165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: \~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
Study NCT05410392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: Home-based physical exercise with the use of a stationary recumbent style bike.
Study NCT05410392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive exercise intervention
Description: Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
Study NCT05410392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of topics
Study NCT04986579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Cap attached to coolant lines connected to a refrigeration unit placed on scalp
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Intravenous Infusion
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Intravenous Infusion
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Intravenous Infusion
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan
Description: Intravenous Infusion
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Intravenous Infusion
Study NCT04986579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: Intravenous Infusion
Study NCT06276231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
Study NCT06276231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
Study NCT05377411 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive training
Description: Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
Study NCT06276231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Injection
Description: 75 mg of Diclofenac intramuscular Injection
Study NCT06276231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Injection
Description: 75 mg of Diclofenac intramuscular Injection
Study NCT05367037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PhysioVP
Description: The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
Study NCT05367037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDD-VPA
Description: In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
Study NCT05577494 — intervention group
Intervention type: OTHER
Intervention: Questionnaire online
Description: Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual.
Study NCT06003309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.